Vaccination Intention Following Receipt of Vaccine Information Through Interactive Simulation vs Text Among COVID-19 Vaccine-Hesitant Adults During the Omicron Wave in Germany.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Feb 2023
Historique:
entrez: 16 2 2023
medline: 25 2 2023
pubmed: 17 2 2023
Statut: epublish

Résumé

In this cross-sectional study, vaccine-hesitant adults presented with an interactive risk ratio simulation were more likely to show positive change in COVID-19 vaccination intention and benefit-to-harm assessment than those presented with a conventional text-based information format. These findings suggest that the interactive risk communication format can be an important tool in addressing vaccination hesitancy and fostering public trust. Cross-sectional study conducted online with 1255 COVID-19 vaccine-hesitant adult residents of Germany in April and May 2022, surveyed using a probability-based internet panel maintained by respondi, a research and analytics firm. Participants were randomized to 1 of 2 presentations on the benefits and adverse events associated with vaccination. Participants were randomized to a text-based description vs an interactive simulation presenting age-adjusted absolute risks of infection, hospitalization, ICU admission, and death after exposure to coronavirus in vaccinated vs unvaccinated individuals relative to the possible adverse effects as well as additional (population-level) benefits of COVID-19 vaccination. Hesitancy toward COVID-19 vaccination is a major factor in stagnating uptake rates and in the risk of health care systems becoming overwhelmed. Absolute change in respondents' COVID-19 vaccination intention category and benefit-to-harm assessment category. To compare an interactive risk ratio simulation (intervention) with a conventional text-based risk information format (control) and analyze change in participants' COVID-19 vaccination intention and benefit-to-harm assessment. Participants were 1255 COVID-19 vaccine-hesitant residents of Germany (660 women [52.6%]; mean [SD] age, 43.6 [13.5] years). A total of 651 participants received a text-based description, and 604 participants received an interactive simulation. Relative to the text-based format, the simulation was associated with greater likelihood of positive change in vaccination intentions (19.5% vs 15.3%, respectively; absolute difference, 4.2%; adjusted odds ratio [aOR], 1.45; 95% CI, 1.07-1.96; P = .01) and benefit-to-harm assessments (32.6% vs 18.0%; absolute difference, 14.6%; aOR, 2.14; 95% CI, 1.64-2.80; P < .001). Both formats were also associated with some negative change. However, the net advantage (positive - negative change) of the interactive simulation over the text-based format was 5.3 percentage points for vaccination intention (9.8% vs 4.5%) and 18.3 percentage points for benefit-to-harm assessment (25.3% vs 7.0%). Positive change in vaccination intention (but not in benefit-to-harm assessment) was associated with some demographic characteristics and attitudes to COVID-19 vaccination; negative changes were not.

Identifiants

pubmed: 36795411
doi: 10.1001/jamanetworkopen.2022.56208
pii: 2801491
pmc: PMC9936332
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Research Support, Non-U.S. Gov't Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2256208

Références

BMC Med Educ. 2022 Oct 26;22(1):741
pubmed: 36289483
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
Perspect Psychol Sci. 2022 May;17(3):631-651
pubmed: 34874213
JAMA Netw Open. 2020 Dec 1;3(12):e2032335
pubmed: 33301021
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):
pubmed: 34292869
Nat Commun. 2022 Dec 6;13(1):7511
pubmed: 36473855
PLoS One. 2017 Aug 23;12(8):e0183024
pubmed: 28832633
PLoS One. 2022 Sep 12;17(9):e0274186
pubmed: 36095020
Nat Rev Nephrol. 2022 Jul;18(7):409-410
pubmed: 35414006
N Engl J Med. 2021 Dec 2;385(23):2132-2139
pubmed: 34614329
Patient Educ Couns. 2022 Jun;105(6):1571-1580
pubmed: 34696941
Vaccine. 2014 Mar 10;32(12):1388-93
pubmed: 24486360
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609

Auteurs

Odette Wegwarth (O)

Department of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany.

Ulrich Mansmann (U)

Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany.

Fred Zepp (F)

Standing Committee on Vaccination (STIKO), Berlin, Germany.

Dagmar Lühmann (D)

Department of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ralph Hertwig (R)

Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany.

Martin Scherer (M)

Department of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH